Sickle Cell Disease Treatment Market to Surge to $29.6 Billion by 2035, Driven by Advanced Gene Therapies

According to the MarketGenics report, the sickle cell disease treatment market is anticipated to grow from USD 5.7 Billion in 2025 to USD 29.6 Billion in 2035 at a CAGR of 17.9% during the forecast. The sickle cell disease treatment market is growing rapidly due to a rise in disease prevalence, rising awareness among patients, and the continuing adoption of novel therapies in North America and Europe. Biopharma companies are supporting innovations in remote patient monitoring and telemedicine consultations and facilitating the adoption and access to AI technology for treatment planning in order to expand personalized, accessible, and efficient care sites.

Telemedicine and connected health devices are gaining momentum because they allow clinicians to objectively monitor patient and disease biomarkers, assessing risk for acute clinical events and optimizing ongoing therapy regimens while providing scalable care modalities, in both mature and emerging health economies. Demand for home-based care in the post-COVID era is accelerating this trend, with an increasing number of patients preferring to be monitored and managed for chronic diseases such as sickle cell disease remotely, enabling contactless interaction with the clinician.

Get the Detailed Industry Analysis (including the Table of Contents, List of Figures, and List of Tables) - from the Sickle Cell Disease Treatment Market Research Report: https://marketgenics.co/press-releases/sickle-cell-disease-treatment-market-20630

Regional Analysis of Global Sickle Cell Disease Treatment Market

North America is at the forefront of the sickle cell disease treatment market, fueled by an advanced healthcare framework, significant R&D ecosystem, leading in novel therapies quickly adopted by patients. In early 2025, Vertex Pharmaceuticals started a partnership with U.S. hospitals to deploy artificial-intelligence based treatment planning platforms and remote patient monitoring programs, which have positively impacted therapy adherence and clinical outcomes.

The Asia Pacific region is rapidly expanding with an increase in healthcare access, improved awareness, and growing disposable incomes. In early 2025, Novartis began partnerships with established medical centers in India and South Korea to both enhance gene therapy trials, as well support mobile sickle cell screening and care units for underrepresented populations.

Europe continues to expand at a steady rate as a result of a comprehensive public healthcare system and initiatives to promote early diagnosis and preventative care. Similar, in late 2024, Bluebird Bio began localized gene therapy programming in Germany and the UK, offered curative treatments to patients, and increased access to modern day sickle cell disease therapies.

Key players in the global sickle cell disease treatment market include prominent companies such as Agios Pharmaceuticals, Inc., AstraZeneca PLC, Beam Therapeutics Inc., Bioverativ Inc. (Sanofi), bluebird bio, Inc., Celgene Corporation (Bristol-Myers Squibb), CRISPR Therapeutics AG, Editas Medicine, Inc., Emmaus Life Sciences, Inc., Forma Therapeutics Holdings, Inc., Fulcrum Therapeutics, Inc., Gamida Cell Ltd., GlycoMimetics, Inc., Graphite Bio, Inc., Imara Inc., Modus Therapeutics AB, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Sangamo Therapeutics, Inc., Vertex Pharmaceuticals Incorporated, and other key players contributing to market growth through innovation, strategic partnerships, and global expansion.

To know more about the Sickle Cell Disease Treatment Market - Download our Sample Report: https://marketgenics.co/download-report-sample/sickle-cell-disease-treatment-market-20630

Impact of Global Tariff Policies on the Global Sickle Cell Disease Treatment Market Growth and Strategy

Import barriers and tariffs present a significant challenge for the sickle cell disease treatment market by increasing the cost of important therapies, gene-editing tools, pharmacological agents, and medical devices. Tariffs on products imported from major manufacturing platforms, like the U.S., Europe, and emerging markets can raise production and distribution costs which could restrict patient access in price-sensitive locations.

In response to these challenges, manufacturers are looking for ways to diversify their supply chains, increase the capacities to produce domestically, and invest in technology and automated manufacturing processes to lessen dependence on imports. In parallel, companies are pursuing digital platforms for logistics and stock management to realize improvements in efficiency and cost. While global trade policies inevitably shift over time, stakeholders will need to deliberate on the influence of barriers and imposed tariffs on treatments for sickle cell disease across affordability, accessibility, and overall delivery.

Buy Now: https://marketgenics.co/buy/sickle-cell-disease-treatment-market-20630

Recent Development and Strategic Overview:

In March 2025, Vertex Pharmaceuticals shared that over 25,000 patients around the world have received the company's approved disease-modifying therapy, which shows the increased uptake of precise pharmacologic treatments for sickle cell disease. To enhance the quality of treatment provided to patients, Vertex reported it has incorporated predictive analytics that leverages artificial intelligence into its patient management platform that advises providers when patients are about to experience a pain crisis, when to dose, and improves patient medication outcomes overall.

In May 2025, bluebird bio has announced that its clinical trials continue to treat more than 1,500 patients who have sickle cell disease, thereby confirming the increasing impact of its gene therapy programs. The company used AI-enabled monitoring tools to track hemoglobin levels and genetic markers in real time to enhance outcomes by correlating therapy changes that could improve safety and the long-term effectiveness of treatment.

Get a preview of our Sickle Cell Disease Treatment Market Playbook - your guide to GTM strategy, competitive intelligence, supplier dynamics, and Consumer Behavior Analysis: https://marketgenics.co/playbook/sickle-cell-disease-treatment-market-20630

Key Trend: Integration of Digital Health and Personalized Therapies Boosting Market Expansion

The market for SCD treatment is experiencing a shift towards personalized, digitally-enabled care. AI-enhanced treatment planning, remote patient monitoring, and mobile health apps are being combined to improve therapy adherence and monitor long-term outcomes.

For example, in 2025, HemoCare Therapeutics launched a digital platform monitored hemoglobin levels in patients, pain episodes, and therapy adherence in real-time, allowing clinicians to modify therapies ahead of time. Moreover, personalized therapies, along with telehealth and real-time monitoring, improve patient safety, reduce complications, and improve overall efficacy of treatment, so these technologies are a primary driver of leading sickle cell disease treatment market expansion.

Contact:

Mr. Debashish Roy

MarketGenics India Pvt. Ltd.

800 N King Street, Suite 304 #4208, Wilmington, DE 19801, United States

USA: +1 (302) 303-2617

Email: sales@marketgenics.co

Website: https://marketgenics.co

About Us

MarketGenics is a global market research and management consulting company empowering decision makers across healthcare, technology, and policy domains. Our mission is to deliver granular market intelligence combined with strategic foresight to accelerate sustainable growth.

We support clients across strategy development, product innovation, healthcare infrastructure, and digital transformation.

This release was published on openPR.